The Ninth Annual RECOMB/ISCB Conference on Regulatory and Systems Genomics, with DREAM Challenges and Cytoscape Workshop is now accepting abstracts for oral presentations and posters. Topics of interest range from Network visualization and analysis to Translational systems biology. (Learn more.)
The Cancer Moonshot is hosting a summit at Howard University, in Washington, D.C. In conjunction with the Summit, the Vice President is announcing a set of new public and private sector actions to drive progress toward ending cancer as we know it. Federal agencies have come together as part of the Cancer Moonshot Task Force and are announcing today additional investments, improved policies, and new private sector partnerships focused on catalyzing new scientific breakthroughs, unleashing the power of data, accelerating bringing new therapies to patients, strengthening prevention and diagnosis, and improving patient access and care. Among the initiatives announced today was the official launch of the first of the Coding4Cancer (C4C) Challenges: the Digital Mammography DREAM Challenge. (Read more.)
DREAM recently both partnered with the Boston Computational Biology and Bioinformatics network and joined the Systems Biology of Human Disease conference to announce winners and present the initial results from the AstraZeneca-Sanger Drug Combination Prediction Challenge. Jonathan Dry and Julio Saez-Rodriguez reported to an audience of over 80 computational biologists how this Challenge became the highest participated of any DREAM challenge to date, with participation from across the globe including individuals qualified in a wide range of disciplines. They highlighted the winning method from Yuanfang Guan (Department of Computational Medicine & Bioinformatics, University of Michigan), and revealed fascinating early insight to the patterns of data and method usage most influential in successful predictions. DREAM were also delighted to welcome Peter Sorger (Professor of Systems Pharmacology, Harvard Medical School) to describe his own take on crowdsourcing and drug combinations at the BCBB event.
A commentary in the most recent issue of the journal Nature discusses how DREAM Challenges and other open competitions bring new minds, skills and collaborations to problems in biomedical research. (Read More)
BCBB is excited to partner with DREAM as they present the results of their Drug Combination Prediction Challenge at a special BCBB Speaker event . ”DREAMing of Better Drug Combinations” (Read more).
An international consortium of groups from Canada, the United States and the United Kingdom have come together to create an innovative, cloud-based, public challenge running on the Google Cloud Platform to optimize the discovery of genetically distinct groups of cells within cancers that could respond differently to treatment and have different risk of spreading. (Read more)
Each year, more than 5,600 Americans are diagnosed with Amyotrophic Lateral Sclerosis (ALS), also called Lou Gehrig’s Disease. This diagnosis usually prompts more questions from patients and family members about longevity and quality of life than what physicians can immediately answer. (Read more)
Today, Prize4Life, Sage Bionetworks and the DREAM community announced the winners of the DREAM ALS Stratification Prize4Life Challenge, a global data analysis competition to computationally identify different subgroups of ALS patients. In ALS, there is currently no way to determine whether someone living with the disease will survive the average of 3-5 years after diagnosis or live with ALS for decades. The goal of the Challenge is to find answers that may inform clinical practice, new trial designs, and ultimately personalized approaches to the discovery and development of new ALS medicines. (Read more)
Winners of the Prostate Cancer DREAM Challenge were formally recognized at the Prostate Cancer Foundation’s 22nd Annual Scientific Retreat, October 8-10, in Washington, D.C. The Prostate Cancer DREAM Challenge is the first research challenge in prostate cancer to marry crowdsourcing with data sharing, paving a new way to tackle key research questions about metastatic castration-resistant prostate cancer (mCRPC), an advanced form of the disease with poor outcomes. (Read more)
We are very excited to announce our latest collaboration here at F1000Research, which is with the excellent team at Dream Challenges. DREAM, which stands for Dialogue for Reverse Engineering Assessment and Methods, has led the way in innovating crowd sourced collaborations between academia, industry and not for profits to answer important biomedical questions that have a significant impact human health. (Read more)